Abstract: One aspect of a terminal according to the present disclosure includes a receiving section that receives a plurality of downlink control channels supporting application of different control resource set pool indices, and a control section that, when an offset between at least one of the plurality of downlink control channels and a physical shared channel scheduled by the plurality of downlink control channels is smaller than a given value, controls reception of the physical shared channel, based on a default TCI state configured for each of control resource set pool indices or the default TCI state configured irrespective of control resource set pool indices.

Abstract: A terminal according to an aspect of the present disclosure includes a control section that determines whether two physical downlink control channel (PDCCH) candidates out of a plurality of PDCCH candidates can be allocated, and a receiving section that receives the two PDCCH candidates, when it is determined that the two PDCCH candidates can be allocated. The two PDCCH candidates are present within a same slot or a same span. The two PDCCH candidates are associated with two search space sets. The two PDCCH candidates are linked to each other. When it is determined that the two PDCCH candidates cannot be allocated, the control section determines whether one or more PDCCH candidates out of the plurality of PDCCH candidates can be allocated. According to an aspect of the present disclosure, PDCCH candidates can be appropriately determined.

Abstract: A terminal according to one aspect of the present disclosure includes a receiving section that receives a medium access control-control element (MAC CE) indicating two active transmission configuration indicator (TCI) states for one control resource set, and a control section that, when an information element of a radio link monitoring (RLM) reference signal is not provided, uses a reference signal in at least one TCI state out of the two active TCI states for RLM. According to one aspect of the present disclosure, it is possible to appropriately perform at least one of RLM and BFD.

Abstract: A radio communication node includes: a control unit that a first communication using a first radio link with a lower node and a second communication using a second radio link with a terminal, wherein the control unit: controls the first communication using a first radio resource based on a configuration of a radio resource used in the first radio link, when performing a simultaneous communication of the first communication and the second communication, and performs the first communication using a second radio resource at least including the first radio resource when a condition is satisfied not to perform the simultaneous communication of the first communication and the second communication.

Abstract: A terminal according to one aspect of the present disclosure includes: a control section that determines a downlink control channel (Physical Downlink Control Channel (PDCCH)) to monitor from among PDCCHs in a plurality of control resource sets (CORESETs) overlapping in time, based on a CORESET having two transmission configuration indication states (TCI states) being activated; and a receiving section that monitors the determined PDCCH. According to one aspect of the present disclosure, it is possible to appropriately address collision of a plurality of downlink control channels.

Abstract: A pharmaceutical composition comprising a small molecule EGFR inhibitor and a preparation method therefor, the composition comprising N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide, an isomer, solvate, hydrate, or pharmaceutically acceptable salt thereof, or a combination thereof that acts as an active ingredient, and at least one pharmaceutically acceptable excipient.

Abstract: A pharmaceutical composition comprising a small molecule EGFR inhibitor and a preparation method therefor, the composition comprising N-(5-((4-(1-cyclopropyl-TH-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide, an isomer, solvate, hydrate, or pharmaceutically acceptable salt thereof, or a combination thereof that acts as an active ingredient, and at least one pharmaceutically acceptable excipient.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.